Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study

著者: Mazyar Shadman, Ian W. Flinn, Moshe Levy, Ryan Porter, John M. Burke, Syed F. Zafar, Jamal Misleh, Edwin Kingsley, Habte Yimer, Benjamin G. Freeman, Subramanya S Rao, Arvind Chaudhry, Praveen K. Tumula, Mitul Gandhi, Sudhir Manda, Dih-Yih Chen, Kunthel By, Linlin Xu, Ye Liu, Rocco J. Crescenzo, Adam Idoine, Xiaoping Zhang, Aileen Cohen, Jane Huang, Jeff P. Sharman - The Lancet 2022 被引用: 89